In patients with CKD (n = 18) the change of NT-proBNP during linagliptin treatment was not significant (−17.0; IRQ −59.3 to 23.0 pg/ml), but was significantly different from the change during placebo (4.5; IQR −57.8 to 109.3 pg/ml; p = 0.022). Here, NPPB is linked to chronic kidney disease.